Fusion company carries out record-breaking experiment
First Light Fusion, based in Yarnton, achieved the highest quartz pressure ever on the Z Machine, an electromagnetic wave generator, at Sandia National Laboratories.
The machine electromagnetically launches projectiles to higher velocities than any other facility.
The First Light Fusion team at Sandia National Laboratories in the US (Image: First Light Fusion) These are used to impact samples of material in order to test their properties at extreme pressures.
First Light used its amplifier technology to reach an output pressure of 3.67 terapascal (TPa), equivalent to 10 times the pressure at the Earth's centre.
This doubles the previous record of 1.85 TPa the company set in February 2024 during its first experiment on the machine.
Dr Jon Skidmore, principal scientist at First Light Fusion, said: "This significant breakthrough further validates First Light Fusion's amplifier technology on the world's most powerful pulsed power facility.
The First Light Fusion team at Sandia National Laboratories in the US (Image: First Light Fusion) "The concept of target-based power amplification successfully demonstrated on the Z machine can enable a simpler and more cost-effective route to commercial fusion across multiple drivers.
"We look forward to continuing to push research boundaries through our collaboration with Sandia National Laboratories."
Dr Greg Rochau, director of pulsed power sciences at Sandia National Laboratories, added: "This tremendous achievement is a testament to the capabilities of First Light Fusion and a good example of how these collaborations are beneficial to the company, Sandia, our national security programme, and the scientific community."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21-07-2025
- Business Wire
IonQ Expands Engineering Leadership Team, Hiring Rick Muller as Vice President of Quantum Systems
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, today announced the appointment of Dr. Rick Muller as Vice President of Quantum Systems. Muller, who joins this month, will lead IonQ's quantum computing systems development team. Muller will be an integral member of the team tasked with delivering on the company's intent to build the world's most powerful quantum computers with 2 million qubits by 2030. His deep technical expertise will also strengthen IonQ's role as a trusted partner for commercial and federal quantum applications. Muller brings decades of experience to IonQ, including his recent work at the Intelligence Advanced Research Projects Activity (IARPA), an organization within the Office of the Director of National Intelligence (ODNI) that conducts research to address the most difficult challenges faced by the U.S. intelligence community. Muller has also held senior positions at Sandia National Laboratories and the California Institute of Technology. 'Rick brings an exceptional blend of scientific insight and federal systems engineering experience, precisely the kind of leadership IonQ needs as we scale toward operational quantum advantage,' said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. 'His track record leading transformative R&D efforts will be instrumental as we expand our quantum computing system capabilities and deepen our partnerships across both commercial and government sectors.' As Director of IARPA, Muller was responsible for implementing research programs in quantum computing, artificial intelligence, biometrics, and text analytics for the U.S. intelligence community. Prior to that, he led the Quantum and Advanced Microsystems group at Sandia National Laboratories and directed the Department of Energy's Quantum Systems Accelerator, one of the flagship centers established under the National Quantum Initiative. Earlier in his career, Muller led the drive for advanced computational capabilities for national security as part of the Joint Program Office for the National Strategic Computing Initiative. He holds a Ph.D. in chemistry from the California Institute of Technology and a B.A. from Rice University, also in chemistry. 'IonQ is at the forefront of evolving quantum computing from research concepts into leading commercial applications,' said Muller. 'Joining IonQ gives me the opportunity to help scale technology that can solve meaningful problems across science, security, and industry. I'm excited to contribute to the next generation of systems that will continue to make quantum computing impactful.' Muller's appointment follows a national search led by PSIRCH, IonQ's executive search partner of record. About IonQ IonQ, Inc. [NYSE: IONQ] is the leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's most complex problems. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results. The company is accelerating its technology roadmap and intends to deliver the world's most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ's advancements in quantum networking also positions the company as a leader in building the quantum internet. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'accelerate,' 'accelerating,' 'accessible,' 'advancements,' 'advancing,' 'aimed,' 'building,' 'can,' 'deepen,' 'delivering,' 'evolving,' 'expand,' 'intends,' 'intent,' 'scale,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to IonQ's quantum computing capabilities and plans; IonQ's technology driving quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the future impacts of IonQ's offerings; and the scalability, performance, impact, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's inability to attract and retain key personnel; or IonQ's inability to effectively integrate its acquisitions of Qubitekk, Inc., Lightsynq Technologies, Inc., and Capella Space Corporation and close its acquisitions of Oxford Ionics Limited and ID Quantique, SA. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.
Yahoo
18-07-2025
- Yahoo
Sandia National Labs builds mobile high-security vault
ALBUQUERQUE, N.M. (KRQE) – A team at Sandia National Laboratories has developed a mobile, high-security vault that can be deployed to protect the nation's most sensitive assets in remote or temporary locations where there is no secure storage. The mobile vault was built in response to a request from the National Nuclear Security Administration's Stockpile Responsiveness Program, according to Sandia National Laboratories. Watch 'Night at the Museum' under the wings at the Nuclear Museum The vault is housed in a 20-foot shipping container, and an electrical engineer developed the vault's access control, backup power, sensors, and alarm systems. The fully functional prototype was designed, constructed, and demonstrated in six months. Sandia's Transportation Safeguards and Surety Program is now in the process of building two additional full-scale prototypes and will participate in Grey Flag 25, a Department of Defense joint exercise that simulates real-world operational challenges to test hardware readiness. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
14-07-2025
- Yahoo
Takeda's oral narcolepsy drug shines in two Phase III trials
Takeda's oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their endpoints in patients with narcolepsy type 1 (NT1) after 12 weeks of treatment. The primary and secondary endpoints measured changes in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions. These were all statistically significant and clinically meaningful improvements, achieving near normal ranges across the broad range of symptoms investigated. The drug also remained generally well-tolerated with a safety profile consistent with other oveporexton studies, with the most common adverse events (AEs) being insomnia, urinary urgency and frequency. No serious treatment-related adverse events were reported. Based on the study results, Takeda plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) and other global regulators during the 2025 fiscal year. Oveporexton (TAK-861) is an investigational oral orexin receptor 2 (OX2R)-selective agonist. It is designed to address the core cause of NT1 by compensating for orexin deficiency, aiming to improve wakefulness and restore normal sleep-wake patterns. Orexin is a natural brain chemical that plays a crucial role in maintaining wakefulness and regulating the sleep-wake cycle. Takeda president Christophe Weber said: 'We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult-to-treat diseases such as narcolepsy type 1.' Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study. In 2020, Jazz Pharmaceuticals' Xywav (calcium, magnesium, potassium, and sodium oxybates) was approved by the FDA and was the first approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years. Other treatment options for NT1 include trying to manage a regular sleeping pattern, as well as therapies, including stimulants such as Provigil (modafinil), Nuvigil (armodafinil), and Ritalin (methylphenidate) to promote wakefulness. Patients may also receive solriamfetol or pitolisant. To help with cataplexy attacks, either sodium oxybate or some antidepressants such as SSRIs [selective serotonin reuptake inhibitors] and SNRIs [serotonin-norepinephrine reuptake inhibitors] can be used to manage symptoms. If approved, GlobalData predicts sales of oveporexton will reach $1bn in 2030. GlobalData is the parent company of Clinical Trials Arena. "Takeda's oral narcolepsy drug shines in two Phase III trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
